Avian specific technologies under development for the
manufacture of pharmaceuticals:

• Direct-Egg Transfection - Non-viral method for the
  transfection of large transgenes into chicken eggs, such
  that transgenic chickens express the recombinant protein
  in the albumin fraction of their eggs.
  
  
• PGC/CEC Stem Cell Technology - Primordial germ cells
  ("PGC") or chicken embryonic cells ("CEC") are harvested
  from developing embryos, grown in culture to allow transfection
  with the selected gene and then the cells are transferred to a
  recipient egg to produce a chimeric chicken. Potentially
  allows for efficient gene insertion or deletion.
  
  

Multi-species transgenic technologies:

• Gene-Testes Transfection - This technology is designed to
  be applicable in many species. The Gene-Testes Transfection
  technology targets the regenerating sperm cells of the testes
  so that the male produces transgenic sperm. Consequently,
  the male can be bred with the objective of generating
  transgenic animals.
  
  
• Cloning - TranXenoGen currently holds a worldwide exclusive
  license to several patents relating to cloning and
  sperm-mediated transgenesis. The patent portfolio, with a filing
  date of February 3, 1993, covers techniques for the
  reprogramming of somatic cell nuclei for the generation of
  cloned and/or transgenic animals.

The platform technologies are protected by in-licensed,
owned and pending patents.